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Hemodialysis vascular access morbidity in the United States. Extensive
morbidity related to hemodialysis vascular access exists among end-
stage renal disease (ESRD) patients, but the risk factors for this
morbidity have not been extensively studied. Medicare ESRD patient
data were obtained from 1984, 1985, and 1986. Hospitalization for
vascular access morbidity (ICD-996. 1, 996.6, or 996.7) was analyzed
among prevalent patients and, using survival analysis, among incident
patients to assess sex, age, race, and underlying cause of renal failure as
risk factors. We found that 15 to 16% of hospital stays among prevalent
ESRD patients were associated with vascular access-related morbidity.
Black race, older age, female sex, and diabetes mellitus as a cause of
kidney failure were all independent risk factors for access-related
morbidity. The rate ratio comparing Blacks to Whites was 1.12 (95%
C.I., 1.09, 1.16); > 64years to 20 to 44 years, 1.53 (1.46, 1.59); men to
women, 0.81 (0.79, 0.84); and diabetes to glomerulonephritis, 1.29
(1.24, 1.35). We conclude that hemodialysis vascular access malfunc-
tion causes much hospitalization among ESRD patients. Women,
Blacks, the elderly, and diabetics appear to be at particularly high risk,
and additional studies are needed to understand these patterns.
Medicare's end-stage renal disease (ESRD) program had
grown to greater than 190,000 individuals by 1989 at a cost of
over $6 billion annually [I]. Approximately 40% of Medicare's
ESRD budget is spent on the procedural costs of delivering
dialysis, with the remainder of expenses arising primarily from
the costs of morbidity and associated hospitalizations [2]. While
numerous studies strongly suggest that complications of vascu-
lar accesses account for a large proportion of hospitalization in
the ESRD population [3—14], few studies have quantified the
burden of vascular access morbidity in the US. Several studies
have explored a limited number of potential clinical risk factors
for access complications such as graft configuration [15], loca-
tion [3], and material [51, but only one has specifically examined
the impact of demographic characteristics on access patency
[16]. Aman, Levin and Smith reported on 91 patients followed
for 24 months and were unable to find a relationship between
access graft survival and sex or race, but their study had limited
statistical power [16]. The current study was undertaken to
provide an estimate of the magnitude of the problem of access-
related morbidity in the US and to explore the relationship of
sex, age, race, and underlying cause of renal failure as risk
factors for early vascular access malfunction.
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Methods
Data sources and study subjects
The Medicare ESRD Program finances care for approxi-
mately 93% of all dialysis and kidney transplant patients in the
US [1, 17, 18]. Medicare's Program Management and Medical
Information System (PMMIS) database records demographic,
modality of dialysis, hospitalization, and survival information
for all Medicare beneficiaries receiving renal replacement ther-
apy, and was the primary data source for this study [17]. The
three primary discharge diagnoses for each hospitalization (date
of birth, date of death, race), and underlying renal diagnosis
were all extracted from PMMIS. Hospital discharge diagnoses
were categorized according to the International Classification
of Disease, 9th Revision (ICD-9) [19].
The PMMIS was electronically searched to identify all Medi-
care beneficiaries receiving renal replacement therapy at any
time during 1984, 1985, or 1986. These patients comprised the
prevalent ESRD patients studied to estimate the magnitude of
vascular access morbidity in the US. A subset of this group of
patients consisted only of individuals beginning renal replace-
ment therapy for ESRD at some time during 1984, 1985, or
1986. These incident ESRD patients were studied to assess the
risk factors for vascular access failure.
Descriptive study of the prevalence of vascular access
morbidity in the US
A descriptive study of the period prevalence of hospitalizable
hemodialysis access morbidity was accomplished by tabulating
all vascular access-related hospital stays among prevalent end-
stage renal disease (ESRD) patients covered by Medicare
health insurance during 1984, 1985, and 1986. Hospitalization
resulting from a vascular access complication was operationally
defined by one or more of the following ICD-9 discharge
diagnosis codes being listed as a primary discharge diagnosis:
996.1 - mechanical complication of (noncardiac) vascular de-
vice, implant, and graft; 996.6 - infection and inflammatory
reaction due to internal prosthetic device, implant, and graft; or
996.7 - other complication of internal prosthetic device, im-
plant, and graft. Vascular access-related hospital stays were
tabulated for each study year and each ICD-9 code, and were
compared to the total number of hospital stays for any reason in
this same time period (Table 1).
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Table 1. Hospitalization in prevalent ESRD cohorts
1984 1985 1986
# Patients 120,139 132,995 145,322
# Hospital stays 150,775 158,634 170,572
# 996.1, 996.6 or 23,701 26,044 29,741
996.7 Stays
Access-related stays 15.7 16.4 17.4
as % total
Access-related 189,608 182,308 208,187
hospital days
Risk factor study of hospitalization
complications
for vascular access
A cohort study of patients initiating renal replacement ther-
apy in 1984, 1985, or 1986 explored the relationship of sex, age,
race, and underlying renal diagnosis to the rate of vascular
access-related hospitalization. Incident patients were identified
using PMMIS data files and were followed until an access
hospitalization (as defined above by ICD-9 code) or until their
follow-up was terminated at death, first treatment with perito-
neal dialysis, transplantation, or at two years after the initiation
of dialysis, whichever occurred first. The date of transplanta-
tion or conversion to peritoneal dialysis was operationally
defined as the date of the first bill for these services in patients'
Medicare insurance files. Thus, patients were only followed
while on hemodialysis. Those patients whose first renal replace-
ment therapy was either peritoneal dialysis or transplantation
were, therefore, excluded from this analysis.
Validation study of ICD-9 discharge diagnoses as proxies for
vascular access-related hospital stays
Validation of ICD-9 diagnosis codes as proxies for hospital-
izations during which a complication of a vascular access was
treated was carried out using ESRD patients from the Hospital
of the University of Pennsylvania during 1984, 1985, and 1986.
Hemodialysis patients discharged during this time period whose
hospitalization was categorized with one or more of the ICD-9
discharge diagnosis codes (996.1, 996.6, or 996.7) were identi-
fied by a computerized search of patient data files. Vascular
access complications were identified in these patients by
searching these same data files for the presence of the specific
ICD-9 procedure codes indicating vascular access malfunction
or by a chart review that revealed a vascular access malfunc-
tion. Three such codes were selected after review of both the
ICD-9 coding manual and cases of known vascular-access-
related hospitalizations at the University of Pennsylvania. They
included: 39.42 - revision of arteriovenous shunt for renal dial-
ysis; 39.43 - removal of arteriovenous shunt for renal dialysis;
and 39.49 - other revision of vascular procedure. A vascular
access problem was defined by one or more of these three
ICD-9 procedure codes in the hospital's electronic database or
by evidence of vascular access malfunction for which the
patient was treated, identified during a primary chart review.
All 229 admissions to the Hospital of the University of
Pennsylvania (HUP) for hemodialysis patients between 1984
and 1986 assigned one or more of the ICD-9 discharge diagnoses
were included in this validation study. One hundred and sixty-
two (7 1%) of these 229 admissions had an associated ICD-9
procedure code (39.42, 39.43, or 39.49) specifically indicating
revision of a vascular access. Primary medical records were
available for review of 38 of the 67 admissions without a
vascular access revision code; 29 medical records were unavail-
able. Thirty-two (84%) of the 38 medical records reviewed
revealed that treatment for a vascular access complication took
place despite the absence of a specific procedure code in the
hospital's computerized data files. Assuming that vascular
access morbidity also occurred in 84% of the 29 stays for which
medical records were unavailable, 218 (95%) of 229 (exact 95%
confidence interval; 92% to 98%) of stays assigned ICD-9 codes
996.1, 996.6, or 996.7 documented clinically-significant vascular
access problems. These results confirm the value of ICD-9
diagnosis codes as proxy measures for vascular access morbid-
ity among hemodialysis patients, the population used for the
risk factor study.
Analysis
The magnitude of vascular access morbidity was calculated
as the annual percentage of hospitalizations for any cause in
prevalent ESRD patients during 1984, 1985, and 1986 that were
labeled with one or more of the ICD-9 diagnosis codes, 996.1,
996.6, or 996.7. The total number of access-related hospital
days was calculated by summing the length of each access-
related stay in days for each study year. No attempt was made
to separate ESRD patients with a functioning renal transplant or
those receiving peritoneal dialysis from those on hemodialysis
for this descriptive prevalence study.
Analysis of the cohort study of risk factors for vascular
access morbidity consisted initially of a description of the
proportion of incident ESRD patients between 1984 and 1986
experiencing an access-related hospitalization, conversion to
peritoneal dialysis, transplantation, death, or two years of
follow-up without any of these events while remaining on
hemodialysis. Outcome data were next described separately for
individual categories of sex, age, race, and underlying cause of
kidney failure.
The proportion experiencing an access hospitalization should
not be directly compared to assess the relative burden of access
morbidity across categories of each of the main study variables.
These proportions reflect not only the number of access-related
hospitalizations, but the person-time spent on hemodialysis,
which is primarily determined by the rates of censoring events,
death, peritoneal dialysis, and transplantation.
A univariate survival analysis of time to access-related hos-
pitalization was carried out for each of the risk factors under
study, that is, sex, age, race, and underlying cause of kidney
failure. Kaplan-Meier survival curves were generated for cate-
gorized levels of each variable and compared using the log rank
test [20]. Finally, a Cox proportional hazards analysis was
performed to assess the joint impact of demographic character-
istics and underlying renal disease on the rate of access-related
hospitalization [21].
As analyses of the incident cohorts (that is, the patients
beginning dialysis) for each of the three study years were
essentially identical to each other, only pooled results are
presented. 89,091 patients developed ESRD in 1984, 1985, and
1986 combined. Of these, 87,544 (98.3%) patients had sufficient
data to be included in the analyses that follow.
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ICD-9 code 1984 1985 1986
996.1 6,079 (26) 5,755 (22) 5,953 (20)
996.6 5,831 (25) 6,837 (26) 7,889 (27)
996.7 11,791 (50) 13,452 (52) 15,899 (53)
Results
Prevalence of hospitalization for vascular access
complications in the US
Between 1984 and 1986 the number of prevalent ESRD
patients in the PMMIS database grew from 120,139 to 145,322.
On average, ESRD patients each experienced 1.26 hospital
stays for any cause in 1984, falling slightly to 1.19 and 1.17 stays
in 1985 and 1986, respectively. Approximately 16% of all
hospital stays were classified with an ICD-9 discharge code
indicating a vascular access complication in 1984, rising slightly
to 17.4% by 1986 (Table 1).
The distribution of diagnoses for the vascular access-related
hospital stays across the three ICD-9 categories evolved over
the three study years. While stays categorized as "mechanical
complication of (noncardjac) vascular device, implant, and
graft" fell from 26% to 20% of all access-related hospitaliza-
tions, the proportion of stays categorized as "infection and
inflammatory reaction due to internal prosthetic device, im-
plant, and graft" and "other complication of internal prosthetic
device, implant, and graft" both increased comparably (Table
2).
Finally, the mean length of hospital stays for access-related
hospitalization fell from eight to seven days between 1984 and
1986, while the total number of hospital days for admissions
identified as having a vascular access problem rose to greater
than 200,000 days (Table 1).
Risk factors for hospitalization for vascular access
complications
By the end of two years of follow-up 19% of all patients had
experienced a vascular access-related hospitalization despite
the fact that 53% of patients had their observation period
shortened due to death (20%), conversion to peritoneal dialysis
(21%), or transplantation (12%). Twenty-eight percent of all
patients remained on hemodialysis at two years not having
experienced a vascular access-related hospitalization.
Sex. A greater proportion of women experienced a vascular
access-related hospital stay (22% vs. 17%) by the end of two
years of follow-up. Although women experienced the same
cumulative risk of peritoneal dialysis as men (21%), women also
had a lower risk of transplantation (8% vs. 13%) and death (20%
vs. 22%). The survival curves presented in Figure 1 demon-
strate the net result that women had a higher rate of access-
related hospitalization than men.
Race. The frequency distribution of race-specific study out-
comes is presented in Table 3. While more Blacks than Whites
(24% vs. 17%) experienced an access-related hospital stay,
Blacks had considerably more time at risk for access problems
as reflected by their lower risk of death, transplantation, and
peritoneal dialysis. Vascular access-related hospitalization-free
survival curves for Blacks, Whites, and patients of other races
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Fig. 1. Sex-specific hospitalization-free vascular access survival
curves using the Kaplan-Meier method. Symbols are: (—) male;
—
—) female. The curves are statistically significantly different from
one another (P < 0.001).
Study
Frequency (row percent)a
Peritoneal
factors N total Access hosp Death dialysis Transplant
Gender
Male 47,505 8,093 (17) 10,252 (22) 10,056 (21) 6,297 (13)
female 40,038 8,756 (22) 7,690 (20) 8,429 (21) 3,401 (8)
Race
Black 24,083 5,858 (24) 4,045 (17) 3,868 (16) 1,608 (7)
White 58,505 10,119 (17) 13,020 (22) 13,787 (24) 7,470 (13)
Other 4,433 800 (18) 773 (17) 766 (17) 595 (14)
Age
<20 2,460 131 (5) 47 (2) 989 (40) 919 (37)
20—44 20,179 2,983 (15) 1,550 (8) 4,979 (25) 5,963 (30)
45—64 32,870 6,175 (19) 5,717 (17) 7,000 (22) 2,724 (8)
>64 32,035 7,560 (24) 10,628 (33) 5,517 (17) 92 (<1)
Diagnosis
Diabetes 24,179 5,193 (21) 5,541 (23) 5,781 (24) 2,248 (9)
HTN 21,138 4,775 (23) 4,901 (23) 3,829 (18) 1,165 (6)
Glom 17,898 3,063 (17) 2,605 (15) 4,231 (24) 3,075 (17)
Other 16,605 3,023 (18) 3,218 (19) 3,704 (22) 2,279 (14)
are presented in Figure 2 and demonstrate that Blacks have a
slightly higher rate of access-related hospitalization than do
either of the other two racial groups (P < 0.001).
Age. The frequency distribution of main study outcomes
stratified by age (Table 3) demonstrates that the elderly (>64
years) experienced more access-related hospital stays than any
other age group. Less peritoneal dialysis and transplantation for
the elderly increased their person-time at risk for access prob-
lems as compared to younger patients, but a greater risk of
death in the elderly reduced their time at risk for access
complications. The age-specific access-related hospitalization-
free survival curves in Figure 3 reveal that the elderly have a
higher rate of access morbidity even after controlling for their
differential survival, transplantation, and peritoneal dialysis
experiences.
Diagnosis. The frequency distribution of study outcomes for
patients with differing etiologies of renal disease is shown in
Table 2. Vascular access-related hospitalization
Table 3. Outcomes of incident cohorts at two years of follow-up
Abbreviations are: HTN, hypertension; Glom, glomerulonephritis.
a Percentages are of the stratum of the corresponding study factor
shown in the first column of each row. Percentages do not total 100%
because the category of patients surviving 2 years without an access
hospitalization, peritoneal dialysis, or transplant are not shown.
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Table 3. The proportion of patients with diabetic renal disease
experiencing an access-related hospital stay was similar to that
for patients with the diagnosis of hypertensive ESRD (21% vs.
23%). Diabetic patients experienced less time at risk for access
problems by virtue of their higher rates of transplantation and
peritoneal dialysis. Patients with glomerulonephritis experi-
enced fewer access-related hospital stays than any other group
except those without a specified diagnosis. The survival curves
shown in Figure 4 demonstrate that diabetic patients have the
highest rate of access-related complications. Except for the
small group of patients with an unknown renal diagnosis,
patients with glomerulonephritis experienced the lowest rate of
access-related hospitalization. These differences were all highly
statistically significant (P < 0.001).
Multivariate analysis
The results of a multivariate Cox proportional hazards anal-
ysis are shown in Table 4. This analytic approach assessed the
independent influence of sex, age, race, and underlying diagno-
sis on the rate of access-related hospitalization, while control-
ling for the potentially confounding influence of the other three.
These results are quite similar to those of the univariate survival
analyses and confirm that the rate ratios between the highest
and lowest risk subgroup for any risk factor, although statisti-
cally significant, were small in magnitude.
Variable
Hazard Ratio
(C.!.) P
Race
Black 1.12 (1.09,1.16) <0.001
White 1.00 (ret) —
Other 0,88 (0.81,0.88) <0.001
Age
>64 1.53 (1.46,1.59) <0.001
45—64 1.05 (1.01,1.10) 0.029
20—44 1.00 (ret) —
<20 0.64 (0.53,0.76) <0.001
Gender
Male 0.81 (0.79,0.84) <0.001
Female 1.00 (ret) —
Diagnosis
Diabetes 1.29 (1 .24,1.35) <0.001
HTN 1.11 (1.06,1.17 <0.001
Other 1.07 (1.02,1.13) <0.001
Glom 1.00 (ret) —
Discussion
This study demonstrates that the occurrence of vascular
access morbidity, as indicated by the ICD-9 diagnoses 996.1,
996.6 or 996.7, is extremely common in the US Medicare ESRD
population. Although the estimated proportion of all hospital
stays associated with vascular access morbidity presented here
may have been overestimated by the inclusion of transplant and
pentoneal dialysis patients, the data validation study suggests
that approximately 90% of admissions for hemodialysis patients
designated by these ICD-9 diagnosis codes are truly associated
with vascular access malfunction. The case mix of dialysis
patients at HUP may not represent the US as a whole and,
therefore, coding for vascular access morbidity may not be
representative of the entire nation. No reasons are apparent,
however, to suspect that discharge coding for vascular access
morbidity at the HUP differs systematically from that per-
formed at other hospitals. Furthermore, the inability of the
prevalence study to consider morbid access events treated in
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Fig. 4. Renal diagnosis-specific hospitalization-free vascular access
survival curves using the Kaplan-Meier method. Symbols are: (—. —)
unknown; (- - -) glomerulonephritis; (——) hypertension; (—) diabe-
tes; (—. —) other. The curves are statistically significantly different
from one another (P < 0.001).
Table 4. Risk factor analysis using proportional hazards modeling
Fig. 2. Race-specific hospitalization-free vascular access survival
curves using the Kaplan-Meier method. Symbols are: (——) Black;(—) White; (- - -) other. The curves are statistically significantly
different from one another (P < 0.001).
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Fig. 3. Age-specific hospitalization-free vascular access survival
curves using the Kaplan-Meier method. Symbols are: (- - -) <20years;(—) 45—64 years; (——) 20—44 years; (— —) >64 years. The curves
are statistically significantly different from one another (P < 0.001).
Abbreviations are: HTN, hypertension; Glom, glomerulonephritis;
C,!., 95% confidence interval.
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the outpatient setting, for example, those treated with throm-
bolytic therapy or angioplasty, makes the estimate of the
burden of access-related morbidity in the US from this study
likely to be an understatement.
Based on the very conservative assumptions that only one-
half of the hospital days for access-related hospital stays are for
the access problem per Se, and that a hospital day costs, on
average, $1500 (based on estimated daily cost of hospitalization
for vascular access failure at the Hospital of the University of
Pennsylvania), more than $150 million is spent annually treating
vascular access morbidity in the US. The figure of $50 million
has been estimated by other investigators based on 1980 infor-
mation, suggesting that current costs of access morbidity to the
Medicare program may be substantially higher [151.
Small differences in access morbidity exist among age-, sex-,
race- and renal disease-specific groups. These small differences
achieved statistical significance because of the large sample
sizes involved in this study. While shorter access-hospitaliza-
tion-free survival is understandable both for elderly patients
and those suffering from diabetes mellitus due to their higher
risk of peripheral vascular disease, the explanation for greater
rates of hospitalization for Blacks and women is less readily
apparent. Differential access to care or utilization of outpatient
versus inpatient services may contribute to these findings.
Alternatively, vascular access surgery for Blacks and women
may systematically differ from that for Whites and men, but no
data are currently available to address this. Differences in the
occurrence of vascular access morbidity between Blacks and
Whites may be due, in part, to physiological differences in their
vascular response to injury. Such physiologic differences have
been postulated to cause greater renovascular damage from
hypertension in Blacks as compared to Whites potentially
accounting, in part, for the excess risk of hypertensive renal
failure in Blacks [22]. Clarification of the role that this physio-
logical heterogeneity across different racial groups plays in
vascular access-related morbidity awaits further study. Finally,
women may suffer greater access-related morbidity because of
the smaller caliber of their vessels. This hypothesis, too, has yet
to be fully investigated.
This study was not able to discern the specific type of
vascular access treated during the hospitalization. Medicare
data do not include clinical information enabling discrimination
among synthetic polytetrafluorethylene access grafts, native
arteriovenous fistulae, and dialysis catheters. The risk factors
for failure of these varied accesses may be quite different. The
necessary pooling of all access types in this study, therefore,
could have masked relationships between demographic risk
factors and specific forms of vascular access.
Although statistically significant incidence rate ratios were
observed in this study, they were small in magnitude. This,
along with the limitations inherent to studies utilizing insurance
claims databases, emphasizes the need for these findings to be
confirmed with additional research. If confirmed, these eleva-
tions of vascular access-related hospitalization rates among
women, the elderly, and Blacks indicate substantial excess
morbidity in and cost to Medicare's ESRD Program given its
enormous size.
In summary, the Medicare ESRD database is a useful tool to
explore the importance of vascular access malfunction. Exten-
sive hospitalization takes place in the US ESRD program to
treat malfunctioning dialysis vascular access grafts consuming
enormous resources. This study found disturbing associations
between both race and gender groups and the rate of access-
related morbidity. Additional studies using primary clinical data
are needed to confirm these findings and to understand better
their relationship to access to care as well as demographic,
surgical, dialytic, and comorbidity factors in individual pa-
tients, so that appropriate interventions can be developed and
implemented to reduce the enormous burden of vascular ac-
cess-related morbidity in the US ESRD population.
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